Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BMS 936559

Drug Profile

BMS 936559

Alternative Names: Anti PD L1; BMS-936559; MDX-1105; PD-L1 inhibitor - Bristol-Myers Squibb

Latest Information Update: 08 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medarex
  • Class Antineoplastics; Antiretrovirals; Antiseptics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Haematological malignancies; HIV infections; Sepsis; Solid tumours

Most Recent Events

  • 14 Sep 2017 Bristol-Myers Squibb terminates due to change in business objectives its phase I/II trial in Sepsis in USA (IV, Infusion) (NCT02576457)
  • 22 Feb 2016 Pharmacokinetics and adverse event results from a phase I trial in HIV Infections presented at 23rd Conference on Retroviruses and Opportunistic Infections (CROI-2016)
  • 01 Dec 2015 Phase-I/II clinical trials in Sepsis in USA (IV, Infusion) (NCT02576457)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top